Stock Market & Financial Investment News

News Breaks February 28, 2012 17:17 EDT VVUS VIVUS reports Q4 EPS (14c), consensus (11c) News For VVUS From The Last 14 Days Check below for free stories on VVUS the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 17, 2013 07:11 EDT VVUS VIVUS urges stockholders to vote on the GOLD proxy card VIVUS mailed a letter to stockholders advising them to protect the value of their investment in VIVUS by voting the GOLD proxy card. The letter stated "VIVUS stockholders face an important decision at the upcoming 2013 VIVUS Annual Meeting of Stockholders. Your board and management team have made substantial progress in laying the foundation for Qsymia, and now we are poised to drive future sales by providing broad access to the millions of patients whose lives would benefit from this important therapy. While much progress has already been made, careful and timely execution of the next phase of our retail commercialization plan will be critical to the success of VIVUS. This phase of our retail commercialization plan, after REMS modification, requires a major pharmaceutical company to reach the primary care physicians. As such, we are in discussions with large pharmaceutical companies to explore opportunities as to how we may work together to maximize sales of Qsymia. We strongly believe that electing First Manhattan nominees at the Annual Meeting will jeopardize the progress we are making, and will throw VIVUS into turmoil. At this critical juncture in the company's history, FMC, which owns less than 10% of the company's stock, is trying to seize control of 100% of the VIVUS Board and your company. We strongly urge you not to jeopardize the important progress your Board and management team are making and risk your investment." June 7, 2013 07:04 EDT VVUS VIVUS drug Qsymia cited in The Journal of Diabetes and Its Complications Subscribe for More Information June 4, 2013 11:17 EDT VVUS First Manhattan mails proxy statement, sends letter to Vivus shareholders Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.